We report on the successful treatment of small-cell prostate cancer in a patient undergoing haemodialysis.
The therapeutic regimen included 300 mg/m2 of carboplatin and 50 mg/m2 of etoposide coupled with radical radiotherapy. Adjustments to the patient's haemodialysis prescription included the use of high flux, a larger dialyser surface area and an increased dialysis time. The parameters used aided tolerance to the drug, allowing the delivery of safe, effective treatment. At an interval of over 12 months post-treatment the patient shows no clinical evidence of recurrent disease. This case provides evidence to encourage the use of chemotherapy in otherwise potentially undertreated haemodialysed patients.
McPartlin A, Grimaldo C, Lyons J, Burke D, Mitra S, Choudhury A. Are you the author?
The Christie NHS Foundation Trust, Manchester, UK; The University of Manchester, Manchester, UK; Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
Reference: Clin Kidney J. 2014 Dec;7(6):593-4.